- Home
- SEATW vs IDYA Comparison
SEATW vs IDYA Comparison
Compare SEATW & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEATW
- IDYA
- Stock Information
- Founded
- SEATW N/A
- IDYA 2015
- Country
- SEATW United States
- IDYA United States
- Employees
- SEATW 768
- IDYA N/A
- Industry
- SEATW Industrial Machinery/Components
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- SEATW Industrials
- IDYA Health Care
- Exchange
- SEATW Nasdaq
- IDYA Nasdaq
- Market Cap
- SEATW N/A
- IDYA 2.2B
- IPO Year
- SEATW N/A
- IDYA 2019
- Fundamental
- Price
- SEATW $0.40
- IDYA $24.73
- Analyst Decision
- SEATW
- IDYA Strong Buy
- Analyst Count
- SEATW 0
- IDYA 12
- Target Price
- SEATW N/A
- IDYA $53.67
- AVG Volume (30 Days)
- SEATW N/A
- IDYA 863.5K
- Earning Date
- SEATW N/A
- IDYA 02-18-2025
- Dividend Yield
- SEATW N/A
- IDYA N/A
- EPS Growth
- SEATW N/A
- IDYA N/A
- EPS
- SEATW N/A
- IDYA N/A
- Revenue
- SEATW N/A
- IDYA $3,922,000.00
- Revenue This Year
- SEATW N/A
- IDYA N/A
- Revenue Next Year
- SEATW N/A
- IDYA $251.89
- P/E Ratio
- SEATW N/A
- IDYA N/A
- Revenue Growth
- SEATW N/A
- IDYA N/A
- 52 Week Low
- SEATW N/A
- IDYA $24.48
- 52 Week High
- SEATW N/A
- IDYA $47.74
- Technical
- Relative Strength Index (RSI)
- SEATW 64.54
- IDYA 37.99
- Support Level
- SEATW $0.16
- IDYA $24.48
- Resistance Level
- SEATW $0.25
- IDYA $26.22
- Average True Range (ATR)
- SEATW 0.02
- IDYA 1.26
- MACD
- SEATW 0.01
- IDYA -0.03
- Stochastic Oscillator
- SEATW 100.00
- IDYA 5.37
About SEATW Vivid Seats Inc. Warrant
Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada and Japan. It operates in two segments namely marketplace and resale.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.